WVE · Company research
Wave Life Sciences Ltd. Ordinary Shares (WVE): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
17records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| New data on medicines that act on genetic messages is coming Nov. 4 from Wave Life Sciences - Stock Titan | New data on medicines that act on genetic messages is coming Nov. 4 from Wave Life Sciences Stock Titan | View source ↗ | Stock Titan | Oct 19, 2026 | neutral | 0 | 0.6 |
| Wave Life Sciences (WVE) Stock Fair Value Moves Lower As Analysts Cut Growth Views - Yahoo Finance | Wave Life Sciences (WVE) Stock Fair Value Moves Lower As Analysts Cut Growth Views Yahoo Finance | View source ↗ | Yahoo Finance | Oct 17, 2026 | neutral | 0 | 0.6 |
| Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight | Over 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bullish | 0.875 | 1 |
| Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight | Over 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bullish | 0.875 | 1 |
| Wave Life Sciences (NasdaqGM:WVE) Stock Forecast & Analyst Predictions - Simply Wall Street | Wave Life Sciences (NasdaqGM:WVE) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 15, 2026 | neutral | 0 | 0.6 |
| Wave Life Sciences, Inc. SEC Filing (Oct 14, 2026) - Stock Titan | Wave Life Sciences, Inc. SEC Filing (Oct 14, 2026) Stock Titan | View source ↗ | Stock Titan | Oct 14, 2026 | neutral | 0 | 0.6 |
| Wave Life Sciences, Inc. (WVE) Stock Price, News, Quote & History - Yahoo! Finance Canada | Wave Life Sciences, Inc. (WVE) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 14, 2026 | neutral | 0 | 0.6 |
| A biotech CEO is scheduled to discuss medicines that use RNA in New York on Oct. 20. - Stock Titan | A biotech CEO is scheduled to discuss medicines that use RNA in New York on Oct. 20. Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| FDA supports a one-year data check for possible faster approval of Wave's treatment. - Stock Titan | FDA supports a one-year data check for possible faster approval of Wave's treatment. Stock Titan | View source ↗ | Stock Titan | Oct 1, 2026 | neutral | 0 | 0.6 |
| GSK selected a liver candidate for development, triggering $12 million for Wave. - Stock Titan | GSK selected a liver candidate for development, triggering $12 million for Wave. Stock Titan | View source ↗ | Stock Titan | Sep 30, 2026 | neutral | 0 | 0.6 |
| Wave Life Sciences (WVE) Stock Looks Cheap After A 68% Fall But Expensive On Sales - Simply Wall Street | Wave Life Sciences (WVE) Stock Looks Cheap After A 68% Fall But Expensive On Sales Simply Wall Street | View source ↗ | Simply Wall Street | Aug 12, 2026 | neutral | 0 | 0.6 |
| Wave Life Sciences: An Fairly Valued RNA Opportunity - Seeking Alpha | Wave Life Sciences: An Fairly Valued RNA Opportunity Seeking Alpha | View source ↗ | Seeking Alpha | Aug 12, 2026 | neutral | 0 | 0.6 |
| Wave Life Sciences (WVE) Stock Sinks As Losses Deepen And Revenue Dries Up - Simply Wall Street | Wave Life Sciences (WVE) Stock Sinks As Losses Deepen And Revenue Dries Up Simply Wall Street | View source ↗ | Simply Wall Street | Jul 31, 2026 | neutral | 0 | 0.6 |
| Wave Life Sciences (WVE) Stock Looks Cheap On Price But Expensive On Sales - Yahoo Finance | Wave Life Sciences (WVE) Stock Looks Cheap On Price But Expensive On Sales Yahoo Finance | View source ↗ | Yahoo Finance | Jul 23, 2026 | neutral | 0 | 0.6 |
| Is Wave Life Sciences Ltd. (WVE) A Good Stock To Buy Now? - Yahoo Finance | Is Wave Life Sciences Ltd. (WVE) A Good Stock To Buy Now? Yahoo Finance | View source ↗ | Yahoo Finance | Jun 13, 2026 | neutral | 0 | 0.6 |
| WVE Stock Edges Up After Positive Early Data For Rare Disease Drug - Stocktwits | WVE Stock Edges Up After Positive Early Data For Rare Disease Drug Stocktwits | View source ↗ | Stocktwits | May 18, 2026 | neutral | 0 | 0.6 |
| A Look At Wave Life Sciences (WVE) Valuation After Sharp Year To Date Share Price Decline - Yahoo Finance | A Look At Wave Life Sciences (WVE) Valuation After Sharp Year To Date Share Price Decline Yahoo Finance | View source ↗ | Yahoo Finance | May 2, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.